| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Financial Officer | Chief Financial Officer | CFO and COO
2 companies
James H Mackaness is Chief Financial Officer at SLNO and has filed Form 4s across 2 companies. James H Mackaness's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $5.2M at current prices.
Historically, James H Mackaness's trades have earned a below-average insider score of 35/100 across 16 rated trades. Over a 12-month horizon, 6.3% of those trades were profitable, with an average 12-month return of -49.5%.
The biggest single holding is SLNO (~$5.2M) as Chief Financial Officer. The SLNO filings lean toward selling, a net 134,906 shares.
James H Mackaness has 29 Form 4 filings on record from May 2015 to December 2025, across 2 companies: Chief Financial Officer at Soleno Therapeutics (SLNO), 2020–2025; CFO and COO at Iridex (IRIX), 2015.
The 79 reported transactions were 44 open-market sales, 16 option exercises, 9 option or other derivative awards and 5 stock awards, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 2 purchases worth about $20K and 14 sales worth about $10.5M.
The largest open-market purchase was 6,060 shares of SLNO at an average $1.65 on June 26, 2020, about $10K.
The largest open-market sale was 90,622 shares of SLNO at an average $69.44 on March 27, 2025, about $6.3M. Twelve months later SLNO was down 55%.
None of the 10 sales since April 2023 was marked as made under a Rule 10b5-1 trading plan.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar 27, 2025 | SLNO Soleno Therapeutics Inc | Chief Financial Officer | Sale+OE | 90,622 | $69.44 | $6,293,177.03 | -46.3% | +27.3% | -55.4% | |
| Jan 3, 2025 | SLNO Soleno Therapeutics Inc | Chief Financial Officer | Sell | 7,874 | $45.78 | $360,460.44 | -6.6% | +55.3% | +1.5% | |
| Oct 1, 2024 | SLNO Soleno Therapeutics Inc | Chief Financial Officer | Sell | 8,077 | $49.43 | $399,241.39 | -6.3% | -8.7% | +21.1% | |
| Aug 29, 2024 | SLNO Soleno Therapeutics Inc | Chief Financial Officer | Sell | 13,531 | $47.43 | $641,782.70 | -9.6% | +19.9% | +45.3% | |
| Aug 6, 2024 | SLNO Soleno Therapeutics Inc | Chief Financial Officer | Sell | 14,983 | $45.60 | $683,201.60 | -9.6% | +20.1% | +73.7% | |
| Jul 1, 2024 | SLNO Soleno Therapeutics Inc | Chief Financial Officer | Sell | 7,190 | $41.54 | $298,653.62 | -11.4% | +19.4% | +95.4% | |
| Apr 1, 2024 | SLNO Soleno Therapeutics Inc | Chief Financial Officer | Sell | 5,175 | $41.34 | $213,937.42 | -7.6% | +1.9% | +64.5% | |
| Dec 11, 2023 | SLNO Soleno Therapeutics Inc | Chief Financial Officer | Sale+OE | 32,482 | $36.41 | $1,182,828.34 | -72.8% | +24.3% | +33.4% | |
| Nov 30, 2023 | SLNO Soleno Therapeutics Inc | Chief Financial Officer | Sell | 4,186 | $28.65 | $119,936.85 | -16.4% | +69.7% | +77.1% | |
| Nov 29, 2023 | SLNO Soleno Therapeutics Inc | Chief Financial Officer | Sell | 8,081 | $27.49 | $222,176.75 | -24.1% | +84.1% | +85.4% |